Paris, 10 Apr 2006

What are the specific characteristics of innovation in pharmaceutical biotechnology? How do biopharmaceutical innovation systems in OECD countries perform and which policies are suitable to foster performance?

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries: Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain. The report summarises the results of in-depth studies, providing a comparative analysis of participating countries' performance in science and innovation in biopharmaceuticals. It highlights specific characteristics of the national biopharmaceutical innovation systems in terms of their international openness and the specific role of demand-side factors in the innovation process. Major systemic failures affecting the functioning of the biopharmaceutical innovation systems are identified. Based on rich evidence, the report draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.

This study forms part of a larger effort to compare innovation processes in different industry sectors and technological fields to provide policy guidance and to more fully elaborate the national innovation systems (NIS) approach to policy making.

Table of contents

Foreword

(English) - available for free download

ߣߣÊÓƵ

(French) - available for free download

• Chapter 1. Introduction

• Chapter 2. Summary of Country Studies:
  • Belgium
  • Finland
  • France
  • Germany
  • Japan
  • The Netherlands
  • Norway
  • Spain

The full volume can be browsed on the

ߣߣÊÓƵ

Organisation for Economic Co-operation and Development